- Alpine Immune Sciences Reports First Quarter 2024 Financial Results
- Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
- Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
- Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
- Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
- Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
- Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
- Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 64.95 |
---|---|
High | 64.97 |
Low | 64.94 |
Bid | 64.92 |
Offer | 64.99 |
Previous close | 64.95 |
Average volume | 1.82m |
---|---|
Shares outstanding | 68.60m |
Free float | 65.53m |
P/E (TTM) | -- |
Market cap | 4.46bn USD |
EPS (TTM) | -0.6837 USD |
Data delayed at least 15 minutes, as of May 15 2024 21:00 BST.
More ▼